What does Carevive do that my EHR doesn’t and how do I access the data?

In this video, John Elliott from Carevive sheds light on the questions surrounding Carevive’s unique offerings and how they differ from the EMR. Acknowledging the valid question of how Carevive stands apart, John explains that Carevive is complementary to the EMR, often fully embedded within it.

What sets Carevive apart is its ability to capture patient experience data, bridging the gaps between consults and infusion visits. While the EMR captures essential clinical data and documentation, it may not encompass the vital patient experience data. Carevive steps in to fill these gaps, providing discrete, trendable patient experience data, enabling proactive management and improved patient outcomes.

Accessing Carevive data can be seamless, as it’s often embedded within the EMR, ensuring an effortless user experience for clinicians. Dashboards offer real-time access to discreet ePROs data, empowering clinicians to take timely actions and improve patient care.

Moreover, from a process improvement perspective, Carevive data provides insights into symptom burden and quality of life for specific tumor types and treatments, guiding care services to focus on the highest severity symptoms.

Recent Episodes

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…